W
WAVEMAN · COMPANY
ZOMDF · Zomedica Corp.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

ZOMDF

Zomedica Corp.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001684144
C-SUITE BUYING · 1☆ WATCH
INSIDER NET · 180D
$142.3K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
2
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
REVENUE GROWTH
+17.4%
XBRL, annual
NET MARGIN
-255.6%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$142.3K over 180 days
more than 78% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
+17.4% year over year
more than 67% of Pharma & Biotech
MARGIN
-255.6% net margin
below 75% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +82.2%
+82.2%12M
+0%+81%+161%+242%2025-092025-102025-122026-032026-052026-072026-09 2026-05-11 · POWERS JOHNNY D bought $43.0K2026-05-20 · Klass Russell Kevin bought $22.0K2026-05-13 · POWERS JOHNNY D bought $22.0K2025-11-06 · Klass Russell Kevin bought $20.2K2025-11-13 · Klass Russell Kevin bought $15.0K2025-11-10 · Klass Russell Kevin bought $12.0K2026-05-08 · POWERS JOHNNY D bought $12.0K2026-05-12 · POWERS JOHNNY D bought $11.0K2026-05-21 · Klass Russell Kevin bought $10.4K2026-05-18 · POWERS JOHNNY D bought $10.0K2026-05-20 · POWERS JOHNNY D bought $9.8K2026-05-21 · Klass Russell Kevin bought $1.3K2026-05-21 · Klass Russell Kevin bought $6052025-11-07 · Klass Russell Kevin bought $5002026-05-19 · POWERS JOHNNY D bought $248
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $142.3K bought by insiders over 180 days. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Zomedica Corp. insiders bought a net $142.3K of stock across 24 Form 4 purchases and sales, with 2 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Klass Russell Kevin
Sr. Vice President, Sales
BUY
2026-05-21
104,000.0
$10.4K
Klass Russell Kevin
BUY
2026-05-21
5,500.0
$605
Klass Russell Kevin
BUY
2026-05-21
11,399.0
$1.3K
POWERS JOHNNY D
Director
BUY
2026-05-20
97,515.0
$9.8K
Klass Russell Kevin
BUY
2026-05-20
200,000.0
$22.0K
24 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 19 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Executive pay vs shareholder return · Larry Heaton
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2023
$651.4K
$1.0M
$643.2K
-13%
2022
$1.3M
-$128.9K
$732.8K
-29%
2021
$5.1M
$2.6M
$415.1K
+33%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$32.0M$27.3M$25.2M$18.9M
GROSS PROFIT$21.7M$19.1M$17.3M$13.5M
OPERATING INCOME$-84.4M$-51.1M$-43.3M$-21.9M
NET INCOME$-81.9M$-47.0M$-34.5M$-17.0M
EPS (DILUTED)-0.08-0.05-0.04-0.02
OPERATING CASH FLOW$-17.6M$-23.6M$-16.0M$-11.7M
CASH$9.0M$7.0M$13.0M$27.4M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →